MEI Pharma Inc
For the period ended Dec 31, 2023. Filed Feb 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 13, 2024
LITS$0.96+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
| For the Three Months Ended December 31, | For the Six Months Ended December 31, | |||
|---|---|---|---|---|
| 2023 | 2022 | 2023 | 2022 | |
| Revenues: | ||||
| Revenue from customers | $— | $32,735 | $752 | $41,465 |
| Revenue from collaboration agreements | — | — | 64,545 | — |
| Total revenues | — | 32,735 | 65,297 | 41,465 |
| Operating expenses: | ||||
| Research and development | 3,912 | 15,313 | 7,397 | 34,776 |
| General and administrative | 8,018 | 8,496 | 14,549 | 15,982 |
| Total operating expenses | 11,930 | 23,809 | 21,946 | 50,758 |
| (Loss) income from operations | (11,930) | 8,926 | 43,351 | (9,293) |
| Other income (expense): | ||||
| Change in fair value of warrant liability | — | 486 | — | 1,603 |
| Interest and dividend income | 869 | 845 | 1,963 | 1,325 |
| Other expense, net | (2) | (4) | (3) | (6) |
| Total other income, net | 867 | 1,327 | 1,960 | 2,922 |
| Net (loss) income | $(11,063) | $10,253 | $45,311 | $(6,371) |
| Net (loss) income per share - basic and diluted | $(1.66) | $1.54 | $6.80 | $(0.96) |
| Weighted-average shares used in computing net (loss) income per share - basic and diluted | 6,663 | 6,663 | 6,663 | 6,663 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.